scholarly journals A NEW APPLICATION OF MALDI BIOTYPER FOR A POTENTIAL USE ON THERAPEUTIC DRUG MONITORING OF VORICONAZOLE

2021 ◽  
Author(s):  
Iker Falces-Romero ◽  
Jesús Mingorance ◽  
Julio García-Rodríguez ◽  
Emilio Cendejas-Bueno
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Human Serum ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Good Reproducibility ◽  
Proof Of Concept ◽  
Concentration Method ◽  
Maldi Biotyper ◽  
Simple Extraction ◽  
Potential Use

We present a proof of concept study on the use of MALDI Biotyper to detect and monitor the levels of voriconazole in human serum. A simple extraction-concentration method and a MALDI Biotyper protocol were developed and a parent ion of voriconazole (1 H+) could be detected and quantified with good reproducibility. Our results point to a new application of MALDI Biotyper for therapeutic drug monitoring.

scholarly journals Are capillary DBS applicable for therapeutic drug monitoring of common antipsychotics? A proof of concept

Bioanalysis ◽  
2015 ◽  
Vol 7 (16) ◽  
pp. 2119-2130 ◽  
Author(s):  
Lisbeth Patteet ◽  
Kristof E Maudens ◽  
Christophe P Stove ◽  
Willy E Lambert ◽  
Manuel Morrens ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Proof Of Concept

scholarly journals A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs

mSphere ◽  
2018 ◽  
Vol 3 (6) ◽  
Author(s):  
Gregory R. Wiedman ◽  
Yanan Zhao ◽  
David S. Perlin
Keyword(s):  
Liquid Chromatography ◽  
Therapeutic Drug Monitoring ◽  
Human Serum ◽  
Drug Monitoring ◽  
Fungal Infections ◽  
Antifungal Drugs ◽  
Therapeutic Drug ◽  
Serum Samples ◽  
Human Serum Samples ◽  
Long Chain

ABSTRACT Clinicians need a better way to accurately monitor the concentration of antimicrobials in patient samples. In this report, we describe a novel, low-sample-volume method to monitor the azole-class antifungal drug posaconazole, as well as certain other long-chain azole-class antifungal drugs in human serum samples. Posaconazole represents an important target for therapeutic drug monitoring (TDM) due to its widespread use in treating invasive fungal infections and well-recognized variability of pharmacokinetics. The current “gold standard” requires trough and peak monitoring through high-pressure liquid chromatography (HPLC) or liquid chromatography-tandem mass spectroscopy (LC-MS/MS). Other methods include bioassays that use highly susceptible strains of fungi in culture plates or 96-well formats to monitor concentrations. Currently, no method exists that is both highly accurate in detecting free drug concentrations and is also rapid. Herein, we describe a new method using reduced graphene oxide (rGO) and a fluorescently labeled aptamer, which can accurately assess clinically relevant concentrations of posaconazole and other long-chain azole-class drugs in little more than 1 h in a total volume of 100 µl. IMPORTANCE This work describes an effective assay for TDM of long-chain azole-class antifungal drugs that can be used in diluted human serum samples. This assay will provide a quick, cost-effective method for monitoring concentrations of drugs such as posaconazole that exhibit well-documented pharmacokinetic variability. Our rGO-aptamer assay has the potential to improve health care for those struggling to treat fungal infections in rural or resource-limited setting.

Therapeutic drug monitoring of linezolid: HPLC-based assays for routine quantification of linezolid in human serum and cerebrospinal fluid

2022 ◽  
pp. ejhpharm-2021-003036
Author(s):  
Stefan Günther ◽  
Andreas Reimer ◽  
Horst Vogl ◽  
Stephan Spenke ◽  
Hanns-Christian Dinges ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Therapeutic Drug Monitoring ◽  
Human Serum ◽  
Drug Monitoring ◽  
Therapeutic Drug

Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study

2022 ◽  
pp. 106513
Author(s):  
Suzanne L. Parker ◽  
Adam D. Irwin ◽  
Francine Hosking ◽  
Deanne August ◽  
Brittany Schoenmaker ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Proof Of Concept ◽  
Concept Study

Toward SERS-based point-of-care approaches for therapeutic drug monitoring: the case of methotrexate

2016 ◽  
Vol 187 ◽  
pp. 485-499 ◽  
Author(s):  
Stefano Fornasaro ◽  
Silvia Dalla Marta ◽  
Marco Rabusin ◽  
Alois Bonifacio ◽  
Valter Sergo
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Quantitative Determination ◽  
Human Serum ◽  
Drug Monitoring ◽  
Surface Enhanced Raman Spectroscopy ◽  
Therapeutic Drug ◽  
Chemotherapeutic Drugs ◽  
Least Squares Regression ◽  
Drug Concentrations ◽  
Oncological Patients

To date, in spite of their toxicity, the plasmatic concentration of most chemotherapeutic drugs is difficult to monitor in oncological patients, because their quantitative determination is expensive and time consuming. This contribution reports a first attempt for the direct quantitative determination of a chemotherapeutic drug in human serum samples by means of Surface Enhanced Raman Spectroscopy (SERS). In this study, SERS substrates constituted by Au nanoparticles deposited on paper by a simple dipping method have been used for rapid (few minutes) analysis of diluted human serum spiked with different concentrations of methotrexate, MTX. The drug concentrations were chosen in a range designed to cover typical therapeutic plasmatic values (from nanomolar to millimolar) in oncological patients, and the pertinent calibration was obtained by Partial Least-Squares Regression (PLSR). Stability selection was employed to evaluate the capability of the PLSR model to accurately predict and extract spectral variations correlated to MTX concentration. Such a quantitative determination is crucial for frequent, and hence adherent, therapeutic drug monitoring, TDM, of chemiotherapic drugs, given their heavy side effects. Its low cost, rapid response and the possibility of obtaining spectra with simple and compact instruments, make SERS particularly apt for implementing effective TDM. The promising results obtained in the analytical validation indicate which steps are to be taken on the way toward a clinical validation with real samples from oncological patients, for MTX as well as for other chemotherapeutic drugs.

Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept

2010 ◽  
Vol 36 (4) ◽  
pp. 332-339 ◽  
Author(s):  
Jason A. Roberts ◽  
Marta Ulldemolins ◽  
Michael S. Roberts ◽  
Brett McWhinney ◽  
Jacobus Ungerer ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Critically Ill ◽  
Drug Monitoring ◽  
Critically Ill Patients ◽  
Therapeutic Drug ◽  
Proof Of Concept
Sign in / Sign up

Export Citation Format

Share Document